GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » 1-Year Sharpe Ratio

Bright Minds Biosciences (XCNQ:DRUG) 1-Year Sharpe Ratio : 0.98 (As of Jul. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-07-04), Bright Minds Biosciences's 1-Year Sharpe Ratio is 0.98.


Competitive Comparison of Bright Minds Biosciences's 1-Year Sharpe Ratio

For the Biotechnology subindustry, Bright Minds Biosciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's 1-Year Sharpe Ratio falls into.


;
;

Bright Minds Biosciences 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Bright Minds Biosciences  (XCNQ:DRUG) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Bright Minds Biosciences 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Executives
Jan Torleif Pedersen Director
Nils Bottler Director
Ryan Cheung Senior Officer
Jeremy Fryzuk Director
Alan Kozikowski 10% Security Holder, Director, Senior Officer
Ian Mcdonald Director